{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:12:39Z","timestamp":1792120359084,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004315.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000}}],"reference-count":81,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004315.pub3","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T13:51:11Z","timestamp":1463147471000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Botulinum toxin type B for cervical dystonia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Raquel E","family":"Marques","sequence":"first","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo S","family":"Duarte","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe B","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Castel\u00e3o","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"CHDI Foundation; 155 Village Boulevard Suite 200 Princeton NJ USA 08540"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Peter","family":"Moore","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Av. Professor Egas Moniz Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Avenida Professor Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"10.1002\/14651858.CD004315.pub3-BIB0001|cit1","first-page":"A292 (S46.003)","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia","volume":"52 (Suppl 2)","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53(7)","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0004|cit3","unstructured":"Factor S Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia Toxins'99 (www.wemove.org) 1999 9"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0003|cit4","first-page":"7","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Factor","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0005|cit5","first-page":"31","article-title":"Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0006|cit6","first-page":"S29","article-title":"The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia","volume":"22;53(7)","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0008|cit8","first-page":"A293 (S46.004)","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia","volume":"52 (Suppl 2)","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0010|cit9","first-page":"1431","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","volume":"7","author":"Factor","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0009|cit10","first-page":"7","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Factor","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0011|cit11","unstructured":"Koller M Wallace JD Willmer-Hulme A Chiang P Murray JJ Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients With cervical dystonia Movement Disorders 2000 31"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0012|cit12","first-page":"S29","article-title":"The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004315.pub3-BIB0013|cit13","first-page":"203","article-title":"A double-blind comparative study to evaluate the efficacy and safety of NerBloc (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia","volume":"65","author":"Kaji","year":"2013","journal-title":"Brain and Nerve"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0014|cit14","first-page":"31","article-title":"Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0016|cit16","first-page":"S29","article-title":"The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0017|cit17","first-page":"2874 (abstract)","article-title":"BotB (Botulinum toxin type B) in the treatment of cervical dystonia (CD) - protocol AN072-008: an interim analysis","volume":"10","author":"American BotB Cervical Dystonia Study Group","year":"1995","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0018|cit18","first-page":"31","article-title":"Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"issue":"11","key":"10.1002\/14651858.CD004315.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/00207454.2010.515047","article-title":"An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinB in subjects with cervical dystonia","volume":"120","author":"Chinnapongse","year":"2010","journal-title":"International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0020|cit20","first-page":"29","article-title":"Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study","volume":"15 (Suppl 2)","author":"Cullis","year":"2000","journal-title":"Movement Disorders"},{"issue":"8","key":"10.1002\/14651858.CD004315.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure","volume":"252","author":"Dressler","year":"2005","journal-title":"Journal of neurology"},{"issue":"7","key":"10.1002\/14651858.CD004315.pub3-BIB0022|cit22","first-page":"25","article-title":"Botulinum toxin type B - onset, duration, and efficacy: comparing dilution with preserved versus nonpreserved saline","volume":"16","author":"Jacob","year":"2003","journal-title":"Cosmetic Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD004315.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","article-title":"Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia","volume":"67","author":"Jankovic","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004315.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/BMR-2002-16102","article-title":"Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia","volume":"16","author":"Lew","year":"2002","journal-title":"Journal of Back and Musculoskeletal Rehabilitation"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.870120526","article-title":"BotB (Botulinum toxin type B): Evaluation of safety and tolerability in Botulinum type A-resistant cervical dystonia patients (preliminary study)","volume":"12(5)","author":"Truong","year":"1997","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Statistics in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004315.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-analysis, Simpson's paradox, and the number needed to treat","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3689\u201396","DOI":"10.1523\/JNEUROSCI.0375-08.2008","article-title":"Long-distance retrograde effects of botulinum neurotoxin","volume":"28","author":"Antonucci","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD004315.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/ene.12650","article-title":"Isolated and combined dystonia syndromes - an update on new genes and their phenotypes","volume":"22","author":"Balint","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004315.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","article-title":"Clinical relevance of Botulinum toxin immunogenicity","volume":"26","author":"Benecke","year":"2012 Apr","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0032|cit32","first-page":"495\u2013504","article-title":"On the question of permeability of the blood\u2013brain barrier to botulinum toxin","volume":"48","author":"Boroff","year":"1975","journal-title":"Int Arch Allergy ApplImmunol."},{"issue":"2","key":"10.1002\/14651858.CD004315.pub3-BIB0033|cit33","first-page":"58","article-title":"Botulinum toxin serotype A for cervical dystonia \u2014 an assessment","volume":"4","author":"Brashear","year":"2008","journal-title":"US Neurol"},{"issue":"10","key":"10.1002\/14651858.CD004315.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008 Jul","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1477-7525-4-69","article-title":"How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure","volume":"4","author":"Bro\u017cek","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0037|cit37","article-title":"Statistical power analysis in the behavioral sciences","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1002\/14651858.CD004315.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mdc3.12131","article-title":"Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology","volume":"2","author":"Comella","year":"2015","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0039|cit39","first-page":"211","article-title":"Clinical assessments of patients with cervical dystonia","volume-title":"Therapy with botulinum toxin","author":"Consky","year":"1994"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3200\u20135","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"Paiva","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0041|cit41","first-page":"tre","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0022-510X(71)90129-8","article-title":"An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse","volume":"14","author":"Duchen","year":"1971","journal-title":"J Neurol Sci."},{"issue":"9237","key":"10.1002\/14651858.CD004315.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","article-title":"Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human","volume":"224(2)","author":"Eleopra","year":"1997","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004150070094","article-title":"A prevalence study of primary dystonia in eight European countries","volume":"247","author":"Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and Botulinum toxin therapy: a sSystematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2015","journal-title":"Neurotox Res"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"400\u20134","DOI":"10.3109\/00016489309135834","article-title":"Botulinum A toxin effects on rat jaw muscle spindles","volume":"113","author":"Filippi","year":"1993","journal-title":"Acta Otolaryngol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/jns.1959.16.1.0055","article-title":"Experimental spasmodic torticollis","volume":"16","author":"Foltz","year":"1959","journal-title":"Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0050|cit50","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010 Dec","journal-title":"Biologics: Targets & Therapy"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","article-title":"Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A","volume":"8(4)","author":"Greene","year":"1993","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1002\/14651858.CD004315.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.55.5.601","article-title":"The neurophysiology of dystonia","volume":"55","author":"Hallett","year":"1998 May","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1002\/14651858.CD004315.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","article-title":"Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response","volume":"50","author":"Hanna","year":"1998 Jun","journal-title":"Neurology"},{"issue":"7414","key":"10.1002\/14651858.CD004315.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0055|cit55","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0056|cit56","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1167\u201379","DOI":"10.1016\/0306-4522(81)90081-6","article-title":"Nerve growth in botulinum toxin poisoned muscles","volume":"6","author":"Holland","year":"1981","journal-title":"Neuroscience."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archneur.1990.00530050070014","article-title":"Natural history of adult-onset idiopathic torticollis","volume":"47","author":"Jahnanshani","year":"1990","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004315.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004315.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0960-8966(96)00041-7","article-title":"Nerve terminal sprouting inbotulinum type-A treated mouse levator auris longus muscle","volume":"6","author":"Juzans","year":"1996","journal-title":"Neuromuscul Disord."},{"issue":"4","key":"10.1002\/14651858.CD004315.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009 Jul-Aug","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1745-6215-15-49","article-title":"Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs)","volume":"15","author":"Macefield","year":"2014","journal-title":"Trials"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"39\u201359","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain","volume":"119-120","author":"Matak","year":"2014 Aug-Sep","journal-title":"Prog Neurobiol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tox.2015.07.003","article-title":"Botulinum neurotoxin type A: Actions beyond SNAP-25?","volume":"335","author":"Matak","year":"2015","journal-title":"Toxicology."},{"issue":"1","key":"10.1002\/14651858.CD004315.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0266462305050154","article-title":"Meta-analysis when only the median survival times are known: a comparison with individual patient data results","volume":"21","author":"Michiels","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"10.1002\/14651858.CD004315.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"M\u00fcller","year":"2009 May","journal-title":"J Neural Transm"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"23:54\u201360","DOI":"10.1016\/j.clinph.2011.05.032","article-title":"Neurophysiological changes after intramuscular injection of botulinum toxin","volume":"123","author":"Palomar","year":"2012","journal-title":"Clin Neurophysiol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"259\u201368","DOI":"10.1098\/rstb.1999.0377","article-title":"Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses","volume":"354","author":"Pellizzari","year":"1999","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"issue":"6","key":"10.1002\/14651858.CD004315.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0070|cit70","unstructured":"The Nordic Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"488\u201396","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","article-title":"Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection","volume":"19","author":"Rosales","year":"1996","journal-title":"Muscle Nerve."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"71\u201380","DOI":"10.1111\/j.1468-1331.2010.03056.x","article-title":"On muscle spindles, dystonia and botulinum toxin","volume":"17","author":"Rosales","year":"2010","journal-title":"Eur J Neurol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","article-title":"Identification of the major steps in botulinum toxin action","volume":"44","author":"Simpson","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading","volume":"318(7197)","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"issue":"14","key":"10.1002\/14651858.CD004315.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: A systematic review and meta-analysis","volume":"27","author":"Steeves","year":"2012 Dec","journal-title":"Movement Disorders."},{"issue":"10","key":"10.1002\/14651858.CD004315.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol."},{"key":"10.1002\/14651858.CD004315.pub3-BIB0077|cit77","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004315.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1745-6215-8-38","article-title":"OMERACT: an international initiative to improve outcome measurement in rheumatology","volume":"8","author":"Tugwell","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD004315.pub3-BIB0079|cit79","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol."},{"issue":"12","key":"10.1002\/14651858.CD004315.pub3-BIB0080|cit80","first-page":"2519\u20132526","article-title":"Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value","volume":"259","author":"Zoons","year":"Dec 2012","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004315.pub3-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004314.pub2","article-title":"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia","author":"Costa","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004315.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:46:36Z","timestamp":1784796396000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004315.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":81,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004315.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]}}}